Filing Details
- Accession Number:
- 0001610717-24-000272
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-05-31 16:26:47
- Reporting Period:
- 2024-05-29
- Accepted Time:
- 2024-05-31 16:26:47
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1676725 | Ideaya Biosciences Inc. | IDYA | Pharmaceutical Preparations (2834) | 474268251 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1890578 | Anthony Michael White | C/O Ideaya Biosciences, Inc. 7000 Shoreline Court, Suite 350 South San Francisco CA 94080 | Chief Scientific Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-05-29 | 28,500 | $12.86 | 28,500 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-05-29 | 27,649 | $36.23 | 851 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-05-29 | 851 | $36.78 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2024-05-29 | 28,500 | $0.00 | 28,500 | $12.86 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
64,000 | 2032-02-29 | No | 4 | M | Direct |
Footnotes
- The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on February 22, 2024.
- This transaction was executed in multiple trades in prices ranging from $35.68 to $36.655, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- This transaction was executed in multiple trades in prices ranging from $36.68 to $36.81, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.